These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38771037)

  • 21. Whole blood real-time quantitative PCR for cytomegalovirus infection follow-up in transplant recipients.
    Garrigue I; Boucher S; Couzi L; Caumont A; Dromer C; Neau-Cransac M; Tabrizi R; Schrive MH; Fleury H; Lafon ME
    J Clin Virol; 2006 May; 36(1):72-5. PubMed ID: 16481215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitation of cytomegalovirus DNA load in dried blood spots correlates well with plasma viral load.
    Limaye AP; Santo Hayes TK; Huang ML; Magaret A; Boeckh M; Jerome KR
    J Clin Microbiol; 2013 Jul; 51(7):2360-4. PubMed ID: 23678066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive factors of spontaneous CMV DNAemia clearance in kidney transplantation.
    Noble J; Gatault P; Sautenet B; Gaudy-Graffin C; Beby-Defaux A; Thierry A; Essig M; Halimi JM; Munteanu E; Alain S; Buchler M
    J Clin Virol; 2018; 99-100():38-43. PubMed ID: 29306112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of an ultrasensitive Cytomegalovirus quantitative nucleic acid test on Cytomegalovirus detection and therapy in renal transplant recipients.
    Beechar VB; Pouch SM; Phadke VK; Karadkhele G; Larsen CP; Woodworth MH
    Transpl Infect Dis; 2024 Feb; 26(1):e14219. PubMed ID: 38158932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection.
    Martín-Gandul C; Pérez-Romero P; Sánchez M; Bernal G; Suárez G; Sobrino M; Merino L; Cisneros JM; Cordero E;
    J Clin Virol; 2013 Jan; 56(1):13-8. PubMed ID: 23131346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pharmacist-driven antimicrobial stewardship intervention targeting cytomegalovirus viremia in ambulatory solid organ transplant recipients.
    Wang N; Athans V; Neuner E; Bollinger J; Spinner M; Brizendine K
    Transpl Infect Dis; 2018 Dec; 20(6):e12991. PubMed ID: 30184302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in cytomegalovirus plasma viral loads measured in allogeneic hematopoietic stem cell transplant recipients using two commercial real-time PCR assays.
    Gracia-Ahufinger I; Tormo N; Espigado I; Solano C; Urbano-Ispizua A; Clari MA; de la Cruz-Vicente F; Navarro D; Pérez-Romero P
    J Clin Virol; 2010 Jun; 48(2):142-6. PubMed ID: 20395168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective study comparing cytomegalovirus antigenemia, DNAemia and RNAemia tests in guiding pre-emptive therapy in thoracic organ transplant recipients.
    Lehto JT; Lemström K; Halme M; Lappalainen M; Lommi J; Sipponen J; Harjula A; Tukiainen P; Koskinen PK
    Transpl Int; 2005 Dec; 18(12):1318-27. PubMed ID: 16297050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors influencing cytomegalovirus DNA load measurements in whole blood and plasma specimens from allogeneic hematopoietic stem cell transplant recipients.
    Vinuesa V; Giménez E; Solano C; Albert E; Torres I; Pérez A; Hernández-Boluda JC; Piñana JL; Navarro D
    Diagn Microbiol Infect Dis; 2019 May; 94(1):22-27. PubMed ID: 30579656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences in Duration and Degree of Cytomegalovirus DNAemia Observed With Two Standardized Quantitative Nucleic Acid Tests and Implications for Clinical Care.
    Meesing A; Germer JJ; Yao JD; Gartner ML; Digmann BJ; Razonable RR
    J Infect Dis; 2020 Jan; 221(2):251-255. PubMed ID: 31504626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Detection of cytomegalovirus antigens and virus DNA in the peripheral blood after organ transplantation].
    Xiao Y; Shi K; Mao X
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Sep; 13(3):287-90. PubMed ID: 12569767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences between the quantitative antigenemia assay and the cobas amplicor monitor quantitative PCR assay for detecting CMV viraemia in bone marrow and solid organ transplant patients.
    Flexman J; Kay I; Fonte R; Herrmann R; Gabbay E; Palladino S
    J Med Virol; 2001 Jul; 64(3):275-82. PubMed ID: 11424115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enumeration of NKG2C+ natural killer cells early following allogeneic stem cell transplant recipients does not allow prediction of the occurrence of cytomegalovirus DNAemia.
    Giménez E; Solano C; Amat P; de la Cámara R; Nieto J; López J; Garcia-Noblejas A; Navarro D
    J Med Virol; 2015 Sep; 87(9):1601-7. PubMed ID: 25802229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients.
    Gimeno C; Solano C; Latorre JC; Hernández-Boluda JC; Clari MA; Remigia MJ; Furió S; Calabuig M; Tormo N; Navarro D
    J Clin Microbiol; 2008 Oct; 46(10):3311-8. PubMed ID: 18753357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human cytomegalovirus immediate-early mRNA detection by nucleic acid sequence-based amplification as a new parameter for preemptive therapy in bone marrow transplant recipients.
    Gerna G; Baldanti F; Lilleri D; Parea M; Alessandrino E; Pagani A; Locatelli F; Middeldorp J; Revello MG
    J Clin Microbiol; 2000 May; 38(5):1845-53. PubMed ID: 10790111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients.
    Lisboa LF; Preiksaitis JK; Humar A; Kumar D
    Transplantation; 2011 Nov; 92(9):1063-8. PubMed ID: 21878838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of two quantitative CMV PCR tests, Cobas Amplicor CMV Monitor and TaqMan assay, and pp65-antigenemia assay in the determination of viral loads from peripheral blood of organ transplant patients.
    Piiparinen H; Höckerstedt K; Grönhagen-Riska C; Lautenschlager I
    J Clin Virol; 2004 Jul; 30(3):258-66. PubMed ID: 15135746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
    Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
    Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight-based dosed valganciclovir prophylaxis.
    Liverman R; Serluco A; Nance G; George R; Rodriguez DS; Deshpande S; Mao C; Garro R; Yildirim I
    Pediatr Transplant; 2023 Jun; 27(4):e14493. PubMed ID: 36945819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating Real-World Experience With Maribavir for Treatment of Refractory/Resistant Cytomegalovirus in Renal Transplant Recipients.
    Beechar VB; Phadke VK; Pouch SM; Mehta AK; Karadkhele G; Larsen CP; Woodworth MH
    Clin Transplant; 2024 Oct; 38(10):e15480. PubMed ID: 39427300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.